Reseachers have identified a biomarker for early detection of liver cancer. With current tests like biopsies, cancer in the liver is often detected in advanced stages, which can limit treatment options and lower overall survival rates. The discovery could have wide-ranging impacts, including more effective diagnosis and precision treatment, and less risk to patients.
This is a game changer. It has the possibility to have many more applications, really for any type of cancer, said Yang. We are already applying it to 10 different types of cancer in the lab.
They hope within 18 months to two years to conduct first clinical trials in patents.
The research builds on a 2019 study published in the journal Nature Communications which identified the first early detection of liver fibrosis using a collagen-targeted protein contrast agent.
Science Advances – Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases
AbstractLiver metastases often progress from primary cancers including uveal melanoma (UM), breast, and colon cancer. Molecular biomarker imaging is a new non-invasive approach for detecting early stage tumors. Here, we report the elevated expression of chemokine receptor 4 (CXCR4) in liver metastases in UM patients and metastatic UM mouse models, and development of a CXCR4-targeted MRI contrast agent, ProCA32.CXCR4, for sensitive MRI detection of UM liver metastases. CXCR4 molecular imaging capability in metastatic and intrahepatic xenotransplantation UM mouse models. ProCA32.CXCR4 enables detecting UM liver metastases as small as 0.1 mm3. Further development of the CXCR4-targeted imaging agent should have strong translation potential for early detection, surveillance, and treatment stratification of liver metastases patients.
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Approximately 50% of UM patients will develop metastases. About 93% of UM metastases occur in the liver, which results in death in almost all cases due to the lack of effective treatments.
The liver is a common site for cancer metastases. UM almost exclusively metastasizes to the liver. The mechanism of the liver-specific metastases is not well understood. One of the hypotheses in the field postulates that tumor cells that overly express CXCR4 hijack the CXCR4/CXCL12 axis during the metastatic process and spread to the liver. This hypothesis is based on the findings that the liver microenvironment in UM is rich in multiple chemoattractants including CXCL12, the natural ligand of CXCR4, and CXCR4 was found to be overexpressed on UM cells in several UM cell line studies. CXCR4 is proposed to be a prognostic marker in multiple malignancies, including acute myelogenous leukemia, breast cancers, colorectal cancers, and cutaneous melanoma. Thus, development of imaging agents for CXCR4 may be used as a diagnostic biomarker in cancer and potentially as a prognostic factor.
In this investigation, they validated the diagnostic value of CXCR4 as an imaging biomarker in UM by demonstrating elevated CXCR4 expression in three different biological systems: UM patient liver metastases, UM cell lines, and an in vivo UM murine model.
Brian Wang is a prolific business-oriented writer of emerging and disruptive technologies. He is known for insightful articles that combine business and technical analysis that catches the attention of the general public and is also useful for those in the industries. He is the sole author and writer of nextbigfuture.com, the top online science blog. He is also involved in angel investing and raising funds for breakthrough technology startup companies.
He gave the recent keynote presentation at Monte Jade event with a talk entitled the Future for You.  He gave an annual update on molecular nanotechnology at Singularity University on nanotechnology, gave a TEDX talk on energy, and advises USC ASTE 527 (advanced space projects program). He has been interviewed for radio, professional organizations. podcasts and corporate events. He was recently interviewed by the radio program Steel on Steel on satellites and high altitude balloons that will track all movement in many parts of the USA.
He fundraises for various high impact technology companies and has worked in computer technology, insurance, healthcare and with corporate finance.
He has substantial familiarity with a broad range of breakthrough technologies like age reversal and antiaging, quantum computers, artificial intelligence, ocean tech,  agtech, nuclear fission, advanced nuclear fission, space propulsion, satellites, imaging, molecular nanotechnology, biotechnology, medicine, blockchain, crypto and many other areas.